Variegation of retroviral vector gene expression in myeloid cells

Gene Therapy

Volumn 7, Issue 2, 2000, Pages 153-166

  Zentilin, L ^a   Qin, G ^a,d   Tafuro, S ^a,e   Dinauer, M C ^b   Baum, C ^c   Giacca, M ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CGD; Chronic granulomatous disease; Gene transfer; Myeloid cells; Retroviral vector

Indexed keywords

CD34 ANTIGEN; DNA; SUPEROXIDE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CLONE; CELL CULTURE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; DNA METHYLATION; EMBRYO; GENE CONSTRUCT; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; TRANSGENE; VIRUS TITRATION; X CHROMOSOME LINKAGE;

EID: 0033951116     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301057     Document Type: Article

References (55)

1. Dunbar CE. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med 1996; 47: 11-20.
2. + bone marrow cells. Blood 1993; 82: 1975-1980.
3. Dunbar CE et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
4. Kohn DB. The current status of gene therapy using hematopoietic stem cells. Curr Opin Pediatr 1995; 7: 56-63.
5. Barranger JA. Haematopoietic stem cell gene transfer. Gene Therapy 1996; 3: 379-380.
6. Larochelle A et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SICD mouse bone marrow: implications for gene therapy. Nature Med 1996; 2: 1329-1336.
7. Malech HL et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997; 94: 12133-12138.
8. + cells in ADA-deficient SCID neonates. Nature Med 1998; 4: 775-780.
9. Roos D. The genetic basis of chronic granulomatous disease. Immunol Rev 1994; 138: 121-157.
10. Zhen L et al. Gene targeting of X chromosome-linked chronic granulomatous disease locus in a human myeloid leukemia cell line and rescue by expression of recombinant gp91-phox. Proc Natl Acad Sci USA 1993; 90: 9832-9836.
11. Zentilin L et al. Functional reconstitution of oxidase activity in X-linked chronic granulomatous disease by retrovirus-mediated gene transfer. Exp Cell Res 1996; 225: 257-267.
12. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
13. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New Engl J Med 1991; 324: 509-516.
14. Wong P, Severns CW, Guyer NB, Wright TM. A unique palindromic element mediates gamma interferon induction of mig gene expression. Mol Cell Biol 1994; 14: 914-922.
15. Tafuro S, Zentilin L, Falaschi A, Giacca M. Rapid retrovirus titration using competitive polymerase chain reaction. Gene Therapy 1996; 3: 679-684.
16. Bowtell DD, Cory S, Johnson GR, Gonda TJ. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J Virol 1988; 62: 2464-2473.
17. Roos D et al. X-CGDbase: a database of X-CGD-causing mutations. Immunol Today 1996; 17: 517-521.
18. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994; 91: 2567-2571.
19. Hildinger M et al. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Gene Therapy 1998; 5: 1575-1579.
20. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 691: 7541-7547.
21. Giacca M et al. Fine mapping of a replication origin of human DNA. Proc Natl Acad Sci USA 1994; 91: 7119-7123.
22. Bird A. The essentials of DNA methylation. Cell 1992; 70: 5-8.
23. Ding C et al. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox. Blood 1996; 88: 1834-1840.
24. Linney E et al. Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells. Nature 1984; 308: 470-472.
25. Grez M, Zornig M, Nowock J, Ziegler M. A single point mutation activates the Moloney murine leukemia virus long terminal repeat in embryonal stem cells. J Virol 1991; 65: 4691-4698.
26. Robbins PB et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 1997; 71: 9466-9474.
27. Wang L, Robbins PB, Carbonaro DA, Kohn DB. High-resolution analysis of cytosine methylation in the 5 long terminal repeat of retroviral vectors. Hum Gene Ther 1998; 9: 2321-2330.
28. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
29. Emerman M, Temin HM. Quantitative analysis of gene suppression in integrated retrovirus vectors. Mol Cell Biol 1986; 6: 792-800.
30. Byun J et al. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy. Gene Therapy 1996; 3: 780-788.
31. Hatzoglou M, Bosch F, Park EA, Hanson RW. Hormonal control of interacting promoters introduced into cells by retroviruses. J Biol Chem 1991; 266: 8416-8425.
32. Vile R, Miller N, Chernajovsky Y, Hart I. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Therapy 1994; 1: 307-316.
33. Byun J, Kim JM, Robbins PD, Kim S. The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site. Gene Therapy 1998; 5: 1441-1444.
34. Seliger B, Killian M, Pfizenmaier K. Distinct mechanisms of interferon-gamma and tumor necrosis factor-alpha action in oncogene-transformed mouse fibroblasts. J Cell Biochem 1988; 38: 205-212.
35. Ghazizadeh S, Carroll JM, Taichman LB. Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol 1997; 71: 9163-9169.
36. Pawliuk R, Eaves CJ, Humphries RK. Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen. Hum Gene Ther 1997; 8: 1595-1604.
37. Baum C et al. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J Virol 1997; 71: 6323-6331.
38. Petersen R, Kempler G, Barklis E. A stem cell-specific silencer in the primer-binding site of a retrovirus. Mol Cell Biol 1991; 11: 1214-1221.
39. Walters MC et al. Enhancers increase the probability but not the level of gene expression. Proc Natl Acad Sci USA 1995; 92: 7125-7129.
40. Walters MC et al. Transcriptional enhancers act in cis to suppress position-effect variegation. Genes Dev 1996; 10: 185-195.
41. Laker C et al. Host cis-mediated extinction of a retrovirus permissive for expression in embryonal stem cells during differentiation. J Virol 1998; 72: 339-348.
42. Robbins PB et al. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci USA 1998; 95: 10182-10187.
43. Jones PL et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19: 187-191.
44. Nan X et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
45. Gautsch JW, Wilson MC. Delayed de novo methylation in teratocarcinoma suggests additional tissue-specific mechanisms for controlling gene expression. Nature 1983; 301: 32-37.
46. Niwa O, Yokota Y, Ishida H, Sugahara T. Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells. Cell 1983; 32: 1105-1113.
47. + cells. Hum Gene Ther 1998; 9: 1561-1570.
48. Schilz AJ et al. High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-free conditions. Blood 1998; 92: 3163-3171.
49. Tucker KA, Lilly MB, Heck L Jr, Rado TA. Characterization of a new human diploid myeloid leukemia cell line (PLB- 985) with granulocytic and monocytic differentiating capacity. Blood 1987; 70: 372-378.
50. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning - A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989.
51. Diviacco S et al. A novel procedure for quantitative polymerase chain reaction by coamplification of competitive templates. Gene 1992; 122: 3013-3020.
52. Kume A, Dinauer MC. Retrovirus-mediated reconstitution of respiratory burst activity in X-linked chronic granulomatous disease cells. Blood 1994; 84: 3311-3316.
53. Porter CD et al. Superoxide production by normal and chronic granulomatous disease (CGD) patient-derived EBV-transformed B-cell lines measured by chemiluminescence-based assays. J Immunol Meth 1992; 155: 151-157.
54. Metcalf D. In vitro cloning techniques for hemopoietic cells: clinical applications. Ann Intern Med 1977; 87: 483-488.
55. Akgun E, Ziegler M, Grez M. Determinants of retrovirus gene expression in embryonal carcinoma cells. J Virol 1991; 65: 382-388.